Fundraising Fox
AltrixBio
Wilmington, US · 5 known investors
Find your way into AltrixBio
Sign up to see every warm intro you have to AltrixBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AltrixBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AltrixBio develops AJN003, a once-daily oral therapy that forms a temporary, non-systemic coating on the stomach and upper gastrointestinal tract to alter nutrient sensing and trigger metabolic and hormonal responses. The platform targets type 2 diabetes and obesity, with potential applications in oral drug delivery.
Founders & leadership
AT
Ali TavakkoliCo-founder
NB
Nancy BriefsExecutive Chair of the Board & FounderNancy Briefs is Executive Chair and Founder of AltrixBio, a biotech company developing an oral therapy for type 2 diabetes and metabolic conditions. She brings experience as a board member and former CEO in digital health, medical devices, and pharmaceuticals, with a track record of raising capital and achieving multiple exits across portfolio companies.
JK
Jeff KarpCo-founder
Board
JB
John BrooksBoard director
Investors · 5
Sand Hill Angelslisted by Sand Hill AngelsMenlo Park · $50K – $2M
How we know: sandhillangels.com · Not right? Tell us
Taihill Venturelisted by Taihill VentureCambridge
How we know: Taihill Venture's portfolio page · Not right? Tell us
Walnut Venture Associateslisted by Walnut Venture AssociatesWellesley
How we know: the VCSheet dataset · Not right? Tell us
xfactor venturesreportedDedham · $100K – $200K
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$7.8M disclosed across 2 rounds · 2019–2025
▶$1.2MraisedJun 2025 · 20 investors · PharmaceuticalsRule 506(c)
▶$1.2MraisedJun 2025 · 20 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- John BrooksDirector
- Jeffrey KarpDirector
- Ali TavakkoliDirector
- Nancy BriefsExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.2M
- Minimum investment
- $10K
- Finders' fees
- $250K
- Proceeds to insiders
- $75K
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06c, 4a5
▶$6.6MraisedJun 2025 · 50 investors · PharmaceuticalsRule 506(c)
▶$6.6MraisedJun 2025 · 50 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Jeffrey KarpDirector
- Nancy BriefsExecutive Officer, Director
- Ali TavakkoliDirector
- John BrooksDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- Minimum investment
- $10K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06c, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Myricx BioMyricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.
Regenx BiosciencesREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
Companies working in the same space as AltrixBio.
In the news
Frequently asked questions
- What does AltrixBio do?
- AltrixBio develops AJN003, a once-daily oral therapy that forms a temporary, non-systemic coating on the stomach and upper gastrointestinal tract to alter nutrient sensing and trigger metabolic and hormonal responses. The platform targets type 2 diabetes and obesity, with potential applications in oral drug delivery.
- Who founded AltrixBio?
- AltrixBio was founded by Ali Tavakkoli, Nancy Briefs, Jeff Karp.
- Who are AltrixBio's investors?
- AltrixBio's investors include Sand Hill Angels, Service Provider Capital, Taihill Venture, Walnut Venture Associates, xfactor ventures.
- How much funding has AltrixBio raised?
- AltrixBio has disclosed $7.8M raised across 2 rounds.
- Where is AltrixBio headquartered?
- AltrixBio is headquartered in Wilmington, US.